Oxford researchers start new trial on the use of anti-TNF to treat COVID-19 in care homes

(University of Oxford) Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. Funded by the COVID-19 Therapeutics Accelerator, an initiative set up by Wellcome, the Bill and Melinda Gates Foundation and Mastercard the AVID-CC trial will enrol up to 750 patients.